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Menopause is a key point moment in the specific aging process of women. It represents a universal evolution in life. Its initiation
is defined by a 12-month amenorrhea following the ultimate menstrual period. It encompasses a series of different biologic and
physiologic characteristics. This period of life appears to spot a decline in a series of skin functional performances initiating
tissue atrophy, withering, and slackness. Any part of the skin is possibly altered, including the epidermis, dermis, hypodermis,
and hair follicles. Hormone replacement therapy (oral and nonoral) and transdermal estrogen therapy represent possible specific
managements for women engaged in the climacteric phase. All the current reports indicate that chronologic aging, climacteric
estrogen deficiency, and adequate hormone therapy exert profound effects on various parts of the skin.
1. Introduction
Aging is a heterogeneous multifaceted process exhibiting
different aspects among animal species and humans. Dis-
tinct aging classifications were thus offered to biologists.
One important distinction recognized the dual presentation
and evolution of germ lineages and somatic cells. Human
senescence is characterized by distinct processes affecting
the somatic and germ lineages. Considering species with
different cell lineages and distinct life histories among tissues,
the aging process needs to be adequately qualified [1].
A distinction is commonly drawn between aging affecting
men and women. It stems from major biologic gender differ-
ences. A variety of intra- and extracellular molecular com-
pounds are commonly but distinctly involved during gender-
related human aging. One of the major issues concerns
estrogen depletion at menopause. Such a feature likely exerts
a prominent influence on women aging in a variety of body
systems including, the cardiovascular system, brain, bones,
joints, and skin [2, 3]. Some physical manifestations pro-
gressively take root at menopause. They commonly include
vasomotor instability, urogenital atrophy, palpitations, and
headaches, as well as bone and joint tenderness, asthenia,
disturbed sleep, tiredness, breast tenderness, and skin outlook
decrement [4].
Natural menopause is clearly a “one-off” process initiated
during the first 12-month amenorrhea following the ultimate
menstrual period.The average menopause age is about 49–51
years, corresponding to the decrement in and loss of ovarian
cyclic activity. Of note, a number of conditions potentially
trigger a premature occurrence of menopause.The transition
phase from regular ovarian cycles to menopause is not a swift
biologic event. Rather, a series of progressive hormonal and
clinical alterations take place during the progressive decline
in ovarian activity [5]. The elapse period between the end of
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the reproductive life and the early stages of postmenopausal
phase is referred to as perimenopause or climacteric. It refers
to the surrounding years both before and after menopause
itself when the process of ovarian decline supervenes asso-
ciated with endocrine and concurrent physiologic changes.
Postmenopause corresponds to the initial year ofmenopausal
amenorrhea and the time thereafter.
The main ailments and medical conditions attributed
to menopause correspond to an increased frequency and
severity in cardiovascular disease and osteoporosis. Of note,
these conditions represent leading causes of mortality in
women all over the world. Inevitably, at menopause human
skin behaves similarly to any other sex steroid-sensitive
tissue. It is commonly subjected to regressive alterations
during women climacteric aging (WCA). Of note, WCA
appearance is largely perceived through the skin presentation
which supposedly reflects at least in part the general health.
2. Skin Aging Diversity
In any human organ system, most of the diverse aging pro-
cesses commonly follow a seemingly linear decrease in both
the expected upmost functional activity and the potential
reserve capacity. However, WCA is not linked to a similar
timetable because it is initiated as a turning point at the
entrant process in women’s aging. It is further noteworthy
that skinWCA is associatedwith a variety of other age-related
physiologic feeling of weakness issued from a series of other
intrinsic and environmental threats [6].
The restricted dual presentation of chronologic and
actinic skin aging was challenged because of its oversimpli-
fication about the global skin evolution in life. A broader list
of seven distinct modalities affecting skin aging was offered
[7]. The major aging promoters included (a) the elapsed
time of life, (b) the endocrine and (c) overall metabolic
status, (d) the individual lifestyle, and (e) the cumulative
exposures to electromagnetic radiations, as well as diverse
repeat mechanical promptings from (f) muscle contractions
and (g) extrinsic forces including earth gravity (Table 1).
Accordingly, WCA of the skin is part of the global endocrine
aging process. Recent years have witnessed progresses in
understanding the hormonal involvement in the overall aging
process [8–10]. A gender perspective is thus clearly required
for a full understanding of skin aging [9, 10].
In such a context, the optimal physical appearance, as
well as the structural integrity and functional capacity of the
skin tissues require the adequate balance between a number
of endocrine influences [6, 8]. Any disturbed activity in
the naturally controlled endocrine system potentially abates
some skin performances [8]. Estrogens and other sex steroids
particularly influence both the skin tissue compositions
and structures [3, 9]. In addition, any decreased estrogen
production during menopause exacerbates a series of other
deleterious age effects in women.
3. Skin Climacteric Aging
Skin represents amajor interface between internal organs and
the environment. It is a complex intricate structure exhibiting
a set of mechanisms connected to the rest of the body. In
particular, it reflects a number of internal characteristics of
the body. It is obvious that a series of genetic and hormonal
influences affect the skin structures and functions causing
gender variations to change with age.
In many Western social groups, a rapid increasing trend
is recognized in the aging segment of the population, par-
ticularly among women. In recent decades, some research
priorities targeted both the physiology and management of
WCA [11]. The regular progress in women life expectancy
led to the increased growth of this population living long
after menopause. Nowadays, women expect to live about one
third of their lives in a potential estrogen deficient state.
Overall, extended longevity coupledwith the fact that women
statistically outlive their partners have generated diverse and
special needs inwomen.ThepotentialWCA impact is present
at the origin of a series of physiologic changes and age-related
diseases.
Before menopause, the regular ovulatory cycle is con-
trolled by complex interactions between diverse endocrine
signals from the hypothalamus, pituitary gland, and ovaries.
It is further modulated by the brain cortex, as well as by
hormones issued from the adrenal and thyroid glands, and
by some peripheral hormone productions as well. Each
ovulatory cycle corresponds to the simultaneous activation
of a few ovarian follicles. Among them, one single follicle
usually becomes dominant and leads to ovulation. In the
women reproductive period, about 200,000 ovarian follicles
give rise to 500 or so mature ovocytes. Hence, ovarian
follicular atresia corresponds to a physiologic dominant
process and represents a key process leading to menopause
[2]. During the regular ovarian cycle, estradiol represents
the physiologic dominant estrogen, reaching a peak level at
ovulation. A mid-cycle uprise of blood levels in the follicular
stimulating hormone (FSH) and luteinizing hormone (LH)
occurs typically. 1
There is evidence that estrogens and other sex steroids
impact many organ systems [2, 5, 9, 10]. In particular, they
influence both the skin composition and biology [5, 10].
The gender influence and the regional skin depositions of
estrogens vary considerably. In particular, estrogen receptors
(ER) were identified at a higher density in women than
in men. They appeared unevenly scattered among different
body locations, with larger densities on genital target organs,
the face, and legs. In these locations, they were particularly
identified in the epidermis, sebaceous hair follicles, and
sweat ducts [2, 12, 13]. They probably influence the overall
corneocyte sizes [14]. By contrast, ER appeared less abundant
or almost absent in the dermis and sweat glands. A high
ER/androgen receptor ratio is found in the vagina, while the
reverse ratio exists in the vulva. Both ER and progesterone
receptors decline in the skin from the climacteric onwards
[2, 12, 13].
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Genetic Genetic (premature aging syndromes,melanotype-phototype-related)
Actinic Ultraviolet and infrared irradiations
Behaviour Diet, tobacco, alcoholic abuse, drugaddiction, and facial expressions
Endocrinology
Pregnancy, physiologic, and hormonal
influences (ovaries, testes, thyroid, adrenals,
growth hormone, etc.)
Catabolism Chronic intercurrent debilitating disease(infections, cancers)
Gravitation Earth gravity
The functional ovarian activity fails during the early
stages of WCA. During the menopause transition, antim-
ullerian hormone , and inhibin B, markers of follicular
reserve and function vanish dramatically and anticipate the
progressive ovarian follicular demise [14]. At menopause, a
significant change takes place in the sources and amounts
of estrogens. Indeed, during the reproductive period, the
main part of estrogen production originates from the active
ovarian follicles. Aftermenopause,most circulating estrogens
are derived from the peripheral conversion of androstene-
dione to estrone. These changes occur gradually with age.
Aromatase activity remains present in fibroblasts, adipocytes,
and sebocytes of postmenopausal women.2
Of note, a dramatic increase in FSH takes place at
menopause. A slow decline follows over the next decades.
Simultaneously, a somewhat modest increase occurs in
LH levels [15]. Contrasting with the decline in estro-
gens and progestins, androgen production remains almost
unaffected during menopause transition. Indeed, circulat-
ing amounts in testosterone, androstenedione, dehydro-
epiandrosterone (DHEA), and DHEA-sulfate (DHEAS) are
not markedly altered during premenopause. However, dur-
ing postmenopause, they decline slowly to about 50% of
their premenopause levels. The postmenopausal ratio andro-
gens/estrogen increased compared to premenopause [16].
4. HRT and Skin Climacteric Aging
For about 70 years, the rationale for hormone replacement
therapy (HRT) in WCA appeared straightforward for many
physicians [17–21]. The positive effect of HRT was first
demonstrated in a large observational cohort study started
in themidseventieth.Therefore, health providers encouraged
women to use HRT as prevention strategy for cardiovascular
disease. Furthermore, the HRT impact on skin thickness
and dermal density was demonstrated early when estro-
gens were initially administered to postmenopausal women.
Such replenishment therapy was therefore considered as an
attempt at alleviating in part skin atrophy and xerosis in
postmenopausal women [2, 5, 6]. However, it remains that
menopause and its specific HRT have not yet resolved a
number of other WCA challenges. Some reluctance emerged
in prescribing HRT. The concern was recently documented,
particularly in the United States, pointing to adverse events,
particularly venous thromboembolism and absence of overall
protective benefit against coronary heart disease associated
with high levels in administered estrogens. Other reports
from Europe were less disturbing. Indeed, women profile
and hormones used in Europe were different from the US.
However, no randomized, controlled trial using European
hormone therapy has been performed and no definite answer
concerning the risk and benefit ratio of HRT on cardio-
vascular risk exists. Anyway, some discrepancies persist in
the current literature. Globally, nowadays HRT appears to
improve a series of climacteric changes in diverse organs
including the skin [22–24]. Recent studies confirmed that
both estrogens and estroprogestins in part suppressed signs
of the climacteric syndrome including genital atrophy and the
risk of osteoporotic fractures [18, 19].
The perimenopause estrogen depletion likely contributes
to and exacerbates the negative effects of aging. It seems
obvious that cutaneous changes developed during the initial
postmenopausal decade are both age- and hormone-related
[16, 25, 26]. Indeed, postmenopausal women commonly com-
plain of xerosis, easy skin withering, bruising, and wrinkling
[8]. In many instances, the climacteric impact on skin, and
its HRT correction proved to be particularly difficult to
objectivate and be quantified by clinical examination alone
[24, 27]. It remains that some relevant aspects were conve-
niently rated on semiquantitative scales. Visual and tactile
perceptions of the skin condition still represent valuable
tools in clinical practice. However, they suffer from limited
sensitivity, specificity, and reproducibility in comparative
assessments performed over a long-term period of time. In
addition, the clinical appearance is sometimes misleading
compared to the actual biologic effects of WCA and HRT.
By contrast, noninvasive objective methods of biometrology
are probably better suited for improving the reliability and
precision of in vivo skin assessments [27]. During the last
few decades, quantitative measurement methods used in
dermatological research improved substantially, providing
means of relevant evaluation of skin functions and charac-
teristics. By this way, some WCA skin alterations are readily
identified during incipient menopause. It remains difficult
to distinguish the consequences of menopause from other
age-related changes due to a decline in growth hormone [8].
Indeed, depletions in both estrogens and growth hormone are
combined in that period of women life.
For years, HRT effects on the skin have deservedly
attracted interest [2, 24, 25, 28], but evidence-based issues
remained unsettled or controversial [25, 29, 30]. It seems
that short term HRT treatments fail to bring marked
improvements on the skin structure [29, 30]. The maximum
prevention at skin aging appears to occur following HRT
administration during the perimenopause [2, 22, 31]. The
value of phytoestrogens and the possible implication of
some hormone disruptors from the environment are not
established so far in skin WCA.
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5. HRT and Skin Epithelia
The perception of WCA is commonly based on the appear-
ance of the skin surface. Globally, it depends on the pro-
cess of stress-induced premature senescence (SIPS) results
from a series of distinct sublethal threats including the
effects of reactive oxygen species and those of a variety
of other chemical insults [32]. Changes include among
others some alterations in the morphologic presentation, as
well as senescence-associated disturbed enzyme activities,
cell cycle dysregulations, disturbed gene expressions, and
telomere shortening. Cells engaged in replicative senescence
share common features with those involved in SIPS [32].
In replicative senescence, telomere shortening is associated
with accumulations of DNA single-strand breaks induced by
oxidative stress.Thus, SIPS probably contributes to the in vivo
accumulation of senescent-like epidermal cells. Furthermore,
DNA damages play a key role in both the regular chronologic
skin aging and photoaging [33]. Estrogen depletion possibly
promotes and activates SIPS [34].
In any subject, the skin surface is traversed by furrows
that intersect in complex ways, creating geometric patterns.
The skin surface markings vary with age. In young women,
the patterns are quite orderly. In WCA, the furrows become
shallower and overall plateaus appear larger with some loss in
regularity, but the overall geometry is retained.
Severe forms of WCA are associated with a dramatic
flattening of the epidermis associated with retraction of
the rete ridges. The keratinocyte renewal is decreased. The
keratinocyte maturation is altered with formation of xerosis
represented by a more compact aspect of corneocyte clumps.
Xerosis is a stratum corneum disturbance interpreted as “dry
skin” by laypeople.This condition indeed results from altered
desquamation often followed by a decreased hydration of
the uppermost corneocytes and a weakening of the skin
barrier function. Both the water-holding capacity and barrier
function of the xerotic stratum corneum were reported to be
restored at least in part following HRT [25, 35, 36]. All these
changes are associated with alteration in the epidermal cell
renewal.
Lip mucosa structure and functions are quite distinct
from those of the surrounding skin. Lip mucosa is subjected
to repeat mechanical promptings and to other physical and
chemical stresses. Its age-related structural changes were
reported to be associated with alterations in its potential
extension and contraction [37, 38]. In addition, the hydration
of the lip surface was markedly different between both lips. It
was claimed that any hormonal effect was unlikely in the age-
related changes in lip surface hydration and lip mechanical
properties [38]. Such contention remains yet unsettled.
6. HRT and the Dermal Extracellular Matrix
It is acknowledged that the dermis thins with aging including
WCA. Accordingly, the individual dermal components have
received much attention in an effort to identify markers of
dermal aging in women. In young individuals, the dermis is a
tough connective tissue composed of networks of fairly stable
fibers, predominately and distinctly composed of collagen
and elastin. Fibrous collagen represents about 80% of the dry
weight of the dermis in young adults. Its fibers are charac-
terized by a high tensile strength and they prevent the skin
frombeing severely torn by usual stretching. Collagen density
represents the packing and compactness of fibrils inside
bundles. Such a structure commonly becomes distorted
following repeat and life-long mechanical constraint. Elastic
fibers make up near 5% of the dermis on sun protracted
areas. They act to recoil the skin to its rest position after
deformation. Dermal cells corresponding to fibroblasts and
dermal dendrocytes synthesize and controlmost components
of the dermal extracellular matrix. Their numerical density
globally declines with aging when they commonly evoke thin
fibrocytes with a shrunken cytoplasmic volume suggesting
some abated metabolic activity.
The dermis commonly shrinks withWCA.The reduction
in dermal collagen packing and content was reported to
occur rapidly after menopause and to gradually progress
thereafter [2]. It was assumed that about 30% of the dermal
collagen vanished in the initial 5 postmenopausal years.
This prominent loss was followed by a slower average 2%
yearly decline over the following two decades [2]. Collagen
networks on sun-protected skin areas are thinner and less
compact in aged people.
The interstitial extracellularmatrix present between colla-
gen bundles contains a mixture of hyaluronic acid, versican,
and other glycosaminoglycans [39]. Dermal water is bound
to these hydrophilic compounds. Such molecular association
protects in part the skin against excessive tissue compression
whilst maintaining its suppleness and preventing atrophic
withering and slackness. Estrogens possibly boost the der-
mal hygroscopic properties through enhanced synthesis of
dermal hyaluronic acid [2]. A possible role for intracellular
versican is further possible although not firmly established
[39].
The global integration of the morphologic, molecular,
and biophysical information gained on the dermal WCA
remains currently somewhat confusing due to the complexity
of quandaries. The same problems exist in the understanding
of the clinical dermal changes which is at best rudimentary.
One major WCA changes in the dermis involves the
organization of the individual collagen bundles. They do
not anymore appear in discrete rope-like bundles of tightly
packed fibres. Rather they progressively appear as aggregates
of loosely women fibers. The overall rearrangement of the
dermal collagen network is responsible for the changes in
the biomechanical properties of the dermis in menopausal
women.
Some facets in HRT contribute to changes in the dermal
physical properties of menopausal women. Indeed, HRT
controls in part the dermal thickness and laxity, and the
collagen content and density, as well as the tissue mechanical
reactivity to stress [2, 23]. From an engineering point of view,
human skin represents a complex load transmitting struc-
ture. It is subjected to self-originated and environmentally
imposed responses. Modalities of HRT administration dif-
fered among trials over time. Diverse estrogens were admin-
istered singly or in combination with cyclic administration
of progesterone-derived compounds. The information about
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skin effects was commonly discussed collectively without
distinguishing these modalities.
At present, no consensus has been reached about the
real value of HRT on dermal climacteric aging. Combined
molecular biology and morphology have deferred compre-
hension of structural changes occurring with aging in the
collagen network and density. Globally, the dermal thickness,
its collagen density, and content were reported to be possibly
maintained in HRT receivers compared to age-matched
untreated women [2, 22]. However, a few other authors
denied any significant HRT effect on the dermal collagen
[29, 30]. Still other researchers contended that various levels
of skin response toHRTwere distinguished.These conditions
encompassed good and poor responders [31–33], the latter
category possibly corresponding to smokers or to women
recently entered in the climacteric period without presenting
a loss in estrogen-replaceable collagen [2].
In menopausal women presenting a low collagen density
in the dermis, estrogen replenishment is expected to initially
correct and later exert a prophylactic action. By contrast,
women with mild reduction in the skin collagen amount
during the initial menopause phase, estrogens apparently
exhibit a prophylactic effect only [2, 40]. Therefore, any
depletion in skin collagen content is expected to be in part
normalized although not overstimulated. It was claimed that
the skin collagen replenishment exhibits regional variability
with an increased effect on the abdomen [2].
Climacteric appears to be responsible for atrophic with-
ering, wrinkling, and slackness, particularly on the forearms
and face. Atrophic withering, fine wrinkling and progressive
deepening of facial creases ensue. The quantitative decrease
in collagen density in the dermis probably participates to
the progressive climacteric skin slackness. Such alterations
were reported to be partially reversed in HRT-treated post-
menopausal women [40, 41]. Increased skin distensibility
and impaired elasticity commonly develop in normal weight
untreated perimenopausal women [27, 42, 43], and this
feature ismitigated byHRT. Such correction helps preventing
skin slackness [41]. Deepening of wrinkles is commonly
associated with these functional changes. In some instances,
HRT exerts a beneficial effect on the facial skin aspect
by reducing the age-related rheological changes without,
however, limiting the number and depth of wrinkles [26, 41].
7. HRT and the Dermal Microvasculature
The dermal arterioles, capillaries, and venules differ from the
microvasculature of other organs due to the distinct thickness
of the vascular vessels. Estrogens appear to control the skin
vascularization in women [44–46]. Menopausal skin flushes
reflect prominent vasodilation particularly on the face, neck,
chest, palms, and soles. They correspond to an active process
depending in part on the net effect of the dermal fibrous rear-
rangements. The flush prevalence during early climacteric
is probably more reported to the estrogen depletion, with a
resulting loss of control in the peripheral microvasculature
tonus. The flush phenomenon is expected to fade at least in
part following HRT. The maximum inducible vasodilation
was reported to be reduced in climacteric women receiving
HRT compared with untreated postmenopausal women [44].
The beneficial effect of HRT on the skin blood flow has,
however, been challenged. HRT users have possibly fewer
chronic leg ulcers and pressure-induced ulcers [47]. In the
elderly, estrogen might increase the wound healing rate. This
finding warrants confirmation before recommendingHRT to
improve wound healing.
8. HRT for Skin and Bones
Osteoporosis is a major feature of WCA. It is commonly
associated with clinical manifestations on the skin present-
ing as atrophic withering, wrinkling, sagging, and laxity.
A correlation was reported between skin biomechanical
properties and bone densities [42, 48]. The combination
of decreased skin thickness, altered dermal biomechanical
functions, and loss of bonemineral density probably presents
the greater sensitivity and specificity in identifying women
postmenopausal vulnerability to osteoporotic fractures.
The potential relationship between osteoporosis and
dermatoporosis is probably important to be noted . The
similarity of HRT effects on both conditions would be
important to be adequately explored in the future. 3
9. Conclusion
The few past decades have witnessed a markedly increased
interest in skin aging on the part of health care providers.
The particular interest in skin WCA paralleled the constant
rise in the number and proportion of women living beyond
menopause. A number of societal issues result from this
demographic shift.
Global aging results from the cumulative and synergistic
effects originated by each of the seven specific aforemen-
tioned causes. The older concept of skin aging immutability
is partially challenged by this way. Increased awareness in the
distinct aging inducers in the skin includingWCApotentially
leads to more business-like skin care managements and
promotes innovative developments of specific preventive
measures.
Clearly, the adequate nature and levels of sex steroids
influence both the skin structural integrity and its optimal
functional capacity. Any reduction and failure in this hor-
mone activity exert a key role in WCA as suggested by the
progressive decline in skin appearance from perimenopause
onwards. Indeed, most women clearly associate climacteric
with a decline in skin presentation and a global negative
feeling in life experience. In particular, a series of skin changes
and failures come to develop at menopause and get worse
afterwards. Yet, some of these aspects remained neglected for
a long time by the biomedical research. However, investiga-
tions about the climacteric and postmenopausal aging of the
skin were initiated in the recent past decades. WCA is being
recognized as a significant and treatable health problem.
Clinical strategies in HRT have advanced in sophistica-
tion over time. It remains that people either conducive or
opponents to HRT contribute to render it a complex issue.
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It remains that HRT administration appears quite effective
on skin, provided adequate patient selection (body weight,
cancer risk, etc), respect of contraindications, and appro-
priate hormones including their nature, dosages, regimens,
and routes of administration. The average HRT duration is
roughly 3 years. HRT commonly increases the well-being and
corrects a series of somatic features in menopausal women.
The effectiveness and increased safety of HRT are expected
in the future. All the foregoing aspects indicate that the
combination of chronologic aging, the climacteric estrogen
deficiency, and HRT exert profound and distinct effects on
various aspects of skin physiology. In many instances the
deleterious effects of low estrogen amounts on the skin show
concurrent manifestations in diverse internal tissues and
organs.
HRT trials are frequently associated with disappointing
compliance. Hesitation to initiate HRT and discontinuation
are commonly experienced. In compliant women, HRT
commonly appears to protect in part the skin from some of
the negative WCA changes.
Integration of updated concepts into patientmanagement
should prove to be critical to optimizing prevention, diag-
nosis, and management of WCA and its related dermatoses.
HRT acts in direct or probably indirect ways on several
distinct skin structures. The effects are mediated by direct
hormonal effects on cells harbouring the adequate specific
receptors. Some hormone-stimulated target cells produce in
a second step paracrine signals to other cells which thus
become indirectly influenced by HRT. With HRT signalling
pathways, the epidermis is boosted, and the dermal water
content is enhanced. As a result, skin represents a target organ
whereHRTbenefits are possibly noticeable by thewomen and
their relatives.
Adverse reactions to HRT are probably the most fre-
quently observed on the skin and breasts including venous
thromboembolism. Knowledge of the complications helps to
prepare the potential patient, to reassure wavering women,
and to avoid annoying skin reactions. Thus the HRT compli-
ance is likely improved, and the number of women enjoying
some beneficial effects of HRT is potentially increased.
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